U.S. markets closed

  • S&P Futures

    4,272.25
    -4.50 (-0.11%)
     

  • Dow Futures

    33,945.00
    -18.00 (-0.05%)
     

  • Nasdaq Futures

    13,468.25
    -25.00 (-0.19%)
     

  • Russell 2000 Futures

    1,989.80
    +0.70 (+0.04%)
     

  • Crude Oil

    87.99
    -0.12 (-0.14%)
     

  • Gold

    1,778.60
    +1.90 (+0.11%)
     

  • Silver

    19.65
    -0.09 (-0.44%)
     

  • EUR/USD

    1.0184
    +0.0004 (+0.04%)
     

  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     

  • Vix

    19.90
    +0.21 (+1.07%)
     

  • GBP/USD

    1.2048
    -0.0004 (-0.03%)
     

  • USD/JPY

    134.8400
    -0.2500 (-0.19%)
     

  • BTC-USD

    23,445.81
    -574.73 (-2.39%)
     

  • CMC Crypto 200

    557.58
    -15.24 (-2.66%)
     

  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     

  • Nikkei 225

    28,984.44
    -238.33 (-0.82%)
     

Should Investors Sell Twitter Before Elon Musk Buys It?

Justin Pope, The Motley Fool
·3 min read
Should Investors Sell Twitter Before Elon Musk Buys It?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • TWTR
  • TSLA

Tesla CEO and billionaire Elon Musk is ratcheting up his efforts to buy social media platform Twitter (NYSE: TWTR) to take it private. Earlier this week, he reportedly arranged $46.5 billion in financing to make a tender offer of $54.20 per share after Twitter's board adopted a poison-pill plan designed to discourage a takeover. Shareholders of Twitter, and the investment community as a whole, are trying to grapple with these events and determine what the best course of action might be.

Continue reading

Recommended Stories

  • Warren Buffett Finally Throws In The Towel On 4 Lousy Stocks

    Warren Buffett likes to say his favorite holding period for an S&P 500 stock is forever. But that's definitely not always the case.

  • FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease

    The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.

  • “Pretty Good Outlook”: 10 Stocks to Buy Now Before the Bull Market Begins

    In this article, we discuss 10 stocks to buy now before the bull market begins. If you want to see more stocks in this selection, check out 5 Stocks to Buy Now Before the Bull Market Begins. JPMorgan Asset Management’s chief global strategist, David Kelly, told Bloomberg on August 12 that stocks could recover and […]

  • Cisco stock pops on fourth-quarter earnings beat

    Yahoo Finance reporter Ines Ferre breaks down Cisco's fourth-quarter earnings results.

  • Apple set to unveil iPhone 14 at upcoming September launch event

    Yahoo Finance tech reporter Allie Garfinkle details Apple's plans to unveil its new iPhone 14 at its September launch event.

  • The Average 401(k) Balance by Age

    How much money people have put away for retirement naturally varies by age. See how your savings stack up.

  • U.S. to end purchase of COVID-19 vaccines as industry pivots to commercial market

    Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.

  • Warren Buffett Loaded Up on These 10 Stocks for the Rest of 2022

    In this article, we discuss the 10 stocks that Warren Buffett loaded up on for the rest of 2022. If you want to see more stocks in this selection, click Warren Buffett Loaded Up on These 5 Stocks for the Rest of 2022. Despite the high inflation and rising rates battering the US economy since […]

  • Synopsys (SNPS) Q3 Earnings and Revenues Top Estimates

    Synopsys (SNPS) delivered earnings and revenue surprises of 2.94% and 2.07%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Billionaire Steve Cohen Pulls the Trigger on These 2 High-Yield Dividend Stocks

    It’s easy to get vertigo, when markets get yanked around in several directions at once. The crazy currents we’ve seen in recent weeks have been a recipe for confusion – a bear turned into a bullish rally, inflation hit a 40+ year peak and then pulled back, the Federal Reserve made some of the most aggressive rate hikes in its history before sounding a dovish note. For the average investor, charting a course through these waters is a daunting task. It is in time like this that some expert advice

  • Did the stock market ‘misinterpret’ Fed again? What strategists say about the reaction to the July minutes

    Minutes of the Fed's July meeting indicate stock-market participants were too quick to price in a “less hawkish” policy outlook, some strategists say.

  • This Is How Many Years an Extra $100K Buys You in Retirement

    Will I outlive my retirement savings? This question dogs many retirement savers who view their accounts, often far shy of $1 million, with dread and fear. After all, aspiring retirees have to plan for longer lifespans, potentially steep medical costs … Continue reading → The post This Chart Shows You How Many Years an Extra $100K Buys You in Retirement appeared first on SmartAsset Blog.

  • 3 Oil & Gas Pipeline Stocks From the Prospering Industry

    Higher production of commodities is boosting demand for pipeline and storage assets, thereby brightening the outlook for the Zacks Oil and Gas - Pipeline MLP industry. Some of the frontrunners in the industry are Enterprise (EPD), Energy Transfer (ET) and Magellan Midstream (MMP).

  • Warren Buffett’s 10 Favorite Dividend Stocks for the Rest of 2022

    In this article, we discuss Warren Buffett’s 10 favorite dividend stocks for the rest of 2022. You can skip our detailed analysis of Buffett’s investment strategy, and go directly to read Warren Buffett’s 5 Favorite Dividend Stocks for the Rest of 2022. In one of his interviews with Business Insider, Buffett mentioned that one of […]

  • Young Bankers Worry About Nights Off Early and Dark Days Ahead

    (Bloomberg) -- On a boat under the Statue of Liberty at happy hour one August Thursday, young Morgan Stanley colleagues sipped champagne and smiled. Two Citigroup Inc. banking analysts left the company’s headquarters by 5:40 p.m. to drink across the street. A young investment-banking analyst who came close to burning out last year now has enough free time to take in Broadway shows.Most Read from BloombergApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesLiz Cheney Prepares for N

  • Bluebird bio nabs major win with first FDA approval following split

    Somerville gene therapy firm bluebird bio Inc. has scored its first approval from the U.S. Food and Drug Administration following its business split late last year.

  • Yellen tells IRS to develop modernization plan in 6 months

    Now that President Joe Biden signed Democrats' expansive climate, tax and health care bill into law, U.S. Treasury Secretary Janet Yellen has directed the IRS to develop a plan within six months outlining how the tax agency will overhaul its technology, customer service and hiring processes.

  • 10 Safe Dividend Stocks with Over 4% Yield

    In this article, we discuss 10 safe dividend stocks with over 4% yield. You can skip our detailed analysis of dividend stocks and their performance, and go directly to read 5 Safe Dividend Stocks with Over 4% Yield. During the current market situation, of all the asset classes, dividend stocks seem to perform well this […]

  • 10 Copper Stocks to Buy Now as Recession Fears Recede

    In this article, we discuss 10 copper stocks to buy now as recession fears recede. If you want to see more stocks in this selection, click 5 Copper Stocks to Buy Now as Recession Fears Recede. Copper prices reached their highest level in more than five weeks on August 10, after data reflected U.S. inflation […]

  • Analyst Forecasts For Applied DNA Sciences, Inc. (NASDAQ:APDN) Are Surging Higher

    Shareholders in Applied DNA Sciences, Inc. ( NASDAQ:APDN ) may be thrilled to learn that the analysts have just...